Physician profile
Adi Carmi
NPI 1922462258
$2,648.00
in general payments reported to CMS, 2019-2025
30 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $331 · 2021: $721 · 2022: $512 · 2023: $554 · 2024: $95.11 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $531.69 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $417.58 | 2021-2023 | Qulipta, Ubrelvy |
| Exact Sciences Corporation | $158.47 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $151.28 | 2021-2023 | |
| Nevro Corp. | $142.33 | 2019 | |
| Edwards Lifesciences Corporation | $125.67 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $122.24 | 2021 | |
| Lilly USA, LLC | $120.25 | 2022-2023 | Mounjaro, Jardiance |
| Teva Pharmaceuticals USA, INC. | $107.71 | 2019-2023 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $99.68 | 2020-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.28 | 2020-2022 | |
| Amarin Pharma, INC. | $66.46 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $63.77 | 2020-2022 | |
| Dexcom, INC. | $59.83 | 2021-2022 | |
| Glaxosmithkline, LLC. | $59.32 | 2020-2024 | Trelegy Ellipta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $47.31 | 2022 | |
| Amgen INC. | $41.49 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.98 | 2021-2023 | Xifaxan |
| Astellas Pharma US INC | $25.17 | 2019-2021 | |
| Pulmonx Corporation | $24.52 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Dynavax Technologies Corporation | $20.68 | 2023 | Heplisav-B |
| Upsher-Smith Laboratories LLC | $20.14 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $19.35 | 2024 | Crysvita |
| Medtronic, INC. | $18.43 | 2024 | Kyphon Express II Kyphopak Tray |
| Heartflow, INC. | $17.29 | 2024 | |
| Philips North America LLC | $15.51 | 2022 | |
| Eisai INC. | $13.53 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.38 | 2022 | |
| Axonics, INC. | $12.24 | 2022 | |
| Insulet Corporation | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adi Carmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.